Halozyme(HALO)2025-02-18 21:06Financial Projections for 2025 - Total revenue for 2025 is expected to be 1,225 million, representing YoY growth of 16% - 23%[1][6] - Adjusted EBITDA for 2025 is projected to be 805 million, with YoY growth of 24% - 32%[1][6] - Non-GAAP diluted EPS for 2025 is estimated at 5.35, reflecting YoY growth of 21% - 30%[1][6] - Royalty revenue for 2025 is anticipated to be 750 million, showing YoY growth of 30% - 35%[6][8] Financial Projections for 2024 - 2024 preliminary total revenue is estimated at 1,020 million[4] - 2024 preliminary adjusted EBITDA is projected to be 625 million[4] - 2024 preliminary non-GAAP diluted EPS is estimated at 4.20[4] Share Repurchase Program - The company announced a new $250 million accelerated share repurchase program[1][2] Revenue Growth Drivers - VYVGART Hytrulo and Darzalex SC are key drivers of 2025 revenue growth[3] ENHANZE Technology - ENHANZE technology has been used in nine commercialized products across over 100 global markets[9] Adjustments and Reconciliations - Adjustments relate to taxes for reconciling items, excess benefits or tax deficiencies from stock-based compensation, and the quarterly impact of other discrete items[22] - Adjustment made for the dilutive effect of Convertible Senior Notes due 2028 when the effect differs on a GAAP and non-GAAP basis for the reporting period[22]